Comparison of basal insulin peglispro and insulin glargine in terms of endogenous glucose production, glucose disposal rate and lipolysis in patients with type 1 diabetes: A randomised, open-label, four-period crossover study

Trial Profile

Comparison of basal insulin peglispro and insulin glargine in terms of endogenous glucose production, glucose disposal rate and lipolysis in patients with type 1 diabetes: A randomised, open-label, four-period crossover study

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Insulin peglispro (Primary) ; Insulin glargine
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 20 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top